Need To Know: Analysts Just Made A Substantial Cut To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Estimates [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business. Following the downgrade, the current consensus from Theravance Biopharma's five analysts is for revenues of US$71m in 2024 which - if met - would reflect a notable 14% increase on its sales over the past 12 months. Losses are expected to be contained, narrowing 19% per share from last year to US$0.76 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$79m and losses of US$0.42 per share in 2024. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts. Check out our latest analysis for Theravance Biopharma The consensus price target fell 14% to US$13.20, implicitly signalling that lower earnings per share are a leading indicator for Theravance Biopharma's valuation. These e
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024PR Newswire
- Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseasePR Newswire
- Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma to Participate in an Upcoming Investor ConferencePR Newswire
TBPH
Earnings
- 8/5/24 - Miss
TBPH
Sec Filings
- 10/24/24 - Form SC
- 9/23/24 - Form 8-K
- 9/10/24 - Form 8-K
- TBPH's page on the SEC website